2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. CRAC Channel
  5. CRAC Channel Inhibitor

CRAC Channel Inhibitor

CRAC Channel Inhibitors (14):

Cat. No. Product Name Effect Purity
  • HY-100831
    YM-58483
    		Inhibitor 99.78%
    YM-58483 (BTP2) is the first selective and potent inhibitor of CRAC channels and subsequent Ca2+ signals. YM-584832 is a blocker of store-operated Ca2+ entry (SOCE).
  • HY-101942
    Zegocractin
    		Inhibitor 99.93%
    Zegocractin (CM-4620) is a calcium-release activated calcium-channel (CRAC channel) inhibitor, with IC50s of 119 nM and 895 nM for Orai1/STIM1 and Orai2/STIM1 channels, respectively.
  • HY-N1370
    Tanshinone IIA sulfonate sodium
    		Inhibitor 98.83%
    Tanshinone IIA sulfonate (sodium) is a derivative of tanshinone IIA, which acts as an inhibitor of store-operated Ca2+ entry (SOCE), and is used to treat cardiovascular disorders.
  • HY-111325
    Synta66
    		Inhibitor 98.32%
    Synta66 is an inhibitor of store-operated calcium entry channel Orai, which forms the pore of the CRAC channel, and used for the research of neurological disease.
  • HY-103310
    MRS1845
    		Inhibitor 99.69%
    MRS1845 is a selective store-operated calcium (SOC) channel inhibitor with an IC50 of 1.7 μM. MRS1845 is an ORAI1 inhibitor. MRS1845 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
  • HY-113618B
    RO2959 monohydrochloride
    		Inhibitor 98.21%
    RO2959 monohydrochloride is a potent and selective CRAC channel inhibitor with an IC50 of 402 nM. RO2959 monohydrochloride is a potent blocker of store operated calcium entry (SOCE) mediated by Orai1/Stim1 channels with an IC50 of 25 nM. RO2959 monohydrochloride is also a potent inhibitor of human IL-2 production, and potently blocks T cell receptor triggered gene expression and T cell functional pathways.
  • HY-113618A
    RO2959 hydrochloride
    		Inhibitor
    RO2959 hydrochloride is a potent and selective CRAC channel inhibitor with an IC50 of 402 nM. RO2959 hydrochloride is a potent blocker of store operated calcium entry (SOCE) mediated by Orai1/Stim1 channels with an IC50 of 25 nM. RO2959 hydrochloride is also a potent inhibitor of human IL-2 production, and potently blocks T cell receptor triggered gene expression and T cell functional pathways.
  • HY-12521
    GSK-5498A
    		Inhibitor 98.14%
    GSK-5498A is a selective CARC channel inhibitor (IC50: 1 μM). GSK-5498A inhibits mediators release from mast cells and pro-inflammatory cytokines release from T cells. GSK-5498A can be used in the research of inflammatory disorders.
  • HY-112913
    SOCE inhibitor 1
    		Inhibitor 99.73%
    SOCE inhibitor 1 is a store-operated calcium entry (SOCE) inhibitor with an IC50 of 4.4 μM.
  • HY-20588
    CRAC intermediate 2
    		Inhibitor 99.63%
    CRAC intermediate 2 is a intermediate compound for CRAC inhibitor synthesis, extracted from patent WO 2013059666A1.
  • HY-147005
    piCRAC-1
    		Inhibitor 98.24%
    piCRAC-1 is a potent, photoinducible Ca2+ release-activated Ca2+ (CRAC) channel inhibitor. piCRAC-1 alleviates thrombocytopenia and hemorrhage.
  • HY-103071
    GSK-5503A
    		Inhibitor
    GSK-5503A is a calcium-release activated calcium (CRAC) channel blocker. GSK-5503A effectively inhibits stromal interaction molecule 1 (STIM1) mediated Orai1 and Orai3 currents in vitro. GSK-5503A can be used for the research of asthma and allergic disorders.
  • HY-110216
    5J-4
    		Inhibitor
    5J-4 is a potent CRAC inhibitor. 5J-4 decreases the numbers of infiltrated mononuclear cell into the CNS, and significantly decreases the population of infiltrated CD4+ population. 5J-4 reduces the symptoms and delayed the onset of EAE (experimental autoimmune encephalomyelitis) in mouse model of inflammation.
  • HY-20587
    CRAC intermediate 1
    		Inhibitor 98.46%
    CRAC intermediate 1 is a key intermediate in the chemical synthesis of a series of CRAC channel inhibitors, detailed information can be found in Patent WO 2010122089 A1, intermediate 9.